Status:

ACTIVE_NOT_RECRUITING

Effect of Grapes in Inflammatory Bowel Disease

Lead Sponsor:

Case Western Reserve University

Collaborating Sponsors:

California Table Grape Commission

Conditions:

Crohn Disease

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut...

Detailed Description

This protocol is designed to investigate the effect of grape powder consumption in Inflammatory Bowel Disease (IBD), in particular how grape powder consumption (provided as 46g/day grape powder; equiv...

Eligibility Criteria

Inclusion

  • Documented diagnosis of Crohns disease. CD outpatients in remission
  • Harvey Bradshaw-index in remission (\<6 score)
  • Capable of providing consent to participate.
  • Able to complete daily surveys and take oral nutrition
  • Able to record daily meal intake

Exclusion

  • Short bowel syndrome.
  • Hospitalized patients.
  • Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients.
  • Known drug abuse.
  • Known parasitic disease of the digestive system.
  • Symptomatic intestinal stricture.
  • Presence of an ostomy.
  • Other conditions that would be a contraindication to consumption of the study diets or preclude the participant from completing the study.
  • Well-founded doubt about the patients cooperation.
  • Existing pregnancy or lactation.
  • History of \<1 natural bowel movements per day.
  • Unable to access to technology that permits the daily completion of study related activities.
  • Change in IBD medication within past 4 weeks.
  • Body mass Index \<16 kg/m or ≥35.
  • Documented C.difficile colitis within four weeks of screening.
  • Known berry or grape allergy
  • No probiotic or antibiotic use for the previous 14 days

Key Trial Info

Start Date :

September 16 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 2 2026

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT05972694

Start Date

September 16 2024

End Date

February 2 2026

Last Update

December 23 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States, 44106